SCH 48461
Latest Information Update: 25 Aug 2009
Price :
$50 *
At a glance
- Originator Schering-Plough
- Class
- Mechanism of Action Cholesterol absorption inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hyperlipidaemia
Most Recent Events
- 25 Aug 2009 Discontinued - Phase-II for Hyperlipidaemia in USA (unspecified route)
- 09 Apr 1998 Suspended-II for Hyperlipidaemia in USA (Unknown route)
- 30 Jul 1997 Investigation in Hyperlipidaemia in USA (Unknown route)